|
CN103002951A
|
|
Process for the preparation of new compound
|
|
WO2010043592A1
|
|
Lipase inhibitors for use for the treatment of obesity
|
|
EP1958637A1
|
|
Pharmaceutical composition for the treatment of IL-8 mediated diseases
|
|
EP1946756A1
|
|
Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
|
|
EP1897533A1
|
|
Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions
|
|
EP1903049A1
|
|
Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyloxy)-phenyl] hexane
|
|
EP1764093A1
|
|
Novel aromatic compounds and their use in medical applications
|
|
EP1764094A1
|
|
Novel multi-cyclic compounds and their use
|
|
EP1764095A1
|
|
Novel nitrocatechol derivatives having selectin ligand activity
|
|
EP1764096A1
|
|
Novel phloroglucinol derivatives having selectin ligand activity
|
|
EP1577289A1
|
|
Non-glycosylated/-glycosidic/-peptidic small molecule selectin inhibitors for the treament of inflammatory disorders
|
